HOME >> BIOLOGY >> NEWS
Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children

NEEDHAM, MA (July 22, 1999): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the publication of the detailed results of a Phase II clinical study of AVANT's investigational rotavirus vaccine in the British medical journal, Lancet. The results of the Phase II efficacy trial suggests that the two-dose oral rotavirus vaccine should be helpful in the prevention of rotavirus disease in young children. The clinical investigators reported that the vaccine provided those treated with nearly 90% protection from disease.

David Bernstein, M.D., the lead investigator at the Cincinnati Children's Hospital Medical Center, in association with his colleagues at The Johns Hopkins University Medical School in Baltimore, and the Pittsburgh Pediatric Research and Pennridge Pediatric Associates in Philadelphia, examined the effectiveness of the AVANT vaccine in infants.

The authors write, "The efficacy of the two-dose 89-12 vaccine reported in this study, 89% against any rotavirus illness, is the highest reported for any multicenter study. This compares to efficacy for the currently approved three-dose vaccine that ranged from 49% to 68%." They also write, "The 89-12 rotavirus vaccine was safe, immunogenic, and provided a high level of protection against rotavirus disease."

Dr. Bernstein commented, "We were very pleased with the high level of protection provided by AVANT's vaccine. The excellent safety and efficacy data reported in this publication, along with the inherent advantages of this vaccine, indicate that further development of this highly effective rotavirus vaccine is warranted."

The double-blind, placebo-controlled Phase II study involved a total of 215 infants, of ages nine to 16 weeks. Infants received two oral doses of vaccine or placebo and were followed by active surveillance through one rotavirus season. In the reported study, rotavirus disease occurred in only two patients in the vaccine group compared to 18 patients in th
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
22-Jul-1999


Page: 1 2

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical trial shows timing of chemotherapy improves survival in breast cancer
11. Clinical services must catch up

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... HOUSTON (PRWEB) , ... August 25, 2020 , ... ... it made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most ... list in 2019 as well, and for this year’s list, reported three-year revenue growth ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, ... that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational ... the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... expo uniting life science, data science, informatics and IT leaders goes VIRTUAL and ... period of uncertainty and change, Bio-IT takes the leadership role of keeping our ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health ... growth, , Known as MediVet Biologics since its formation in ... The new Ardent Animal Health will build on its base of innovative therapies ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell ... into a strategic partnership whereby Catalent will provide support for the development, manufacturing, ...
(Date:7/18/2020)... ... 2020 , ... After research model surgery and catheter implantation, the long journey ... the beginning of a successful study, while protecting and accessing the catheter or device ... of Surgery from Envigo in a live webinar on Wednesday, ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
Breaking Biology Technology:
Cached News: